XPO1 and breast cancer: This finding is in accordance with previous results obtained in the HER+ breast cancer cell line SKBR3 showing that the XPO1 antagonist KPT-276 repressed survivin transcription by inhibiting CBP-mediated STAT3 acetylation and blocking STAT3 binding to the survivin promoter [25].